NasdaqGM - Delayed Quote • USD
Intellia Therapeutics, Inc. (NTLA)
At close: 4:00 PM EDT
After hours: 6:35 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
52,604.00
36,275.00
52,121.00
33,053.00
57,994.00
Operating Expense
569,940.00
551,566.00
510,285.00
300,903.00
194,577.00
Operating Income
-517,336.00
-515,291.00
-458,164.00
-267,850.00
-136,583.00
Net Non Operating Interest Income Expense
50,484.00
49,832.00
8,542.00
1,283.00
2,352.00
Other Income Expense
-18,650.00
-15,733.00
-24,564.00
-1,325.00
--
Pretax Income
-485,502.00
-481,192.00
-474,186.00
-267,892.00
-134,231.00
Net Income Common Stockholders
-485,502.00
-481,192.00
-474,186.00
-267,892.00
-134,231.00
Diluted NI Available to Com Stockholders
-485,502.00
-481,192.00
-474,186.00
-267,892.00
-134,231.00
Basic EPS
-5.37
-5.42
-6.16
-3.78
-2.40
Diluted EPS
-5.37
-5.42
-6.16
-3.78
-2.40
Basic Average Shares
90,702.50
88,770.00
76,972.00
70,894.00
55,987.00
Diluted Average Shares
90,702.50
88,770.00
76,972.00
70,894.00
55,987.00
Total Operating Income as Reported
-517,336.00
-515,291.00
-458,164.00
-267,850.00
-136,583.00
Total Expenses
569,940.00
551,566.00
510,285.00
300,903.00
194,577.00
Net Income from Continuing & Discontinued Operation
-485,502.00
-481,192.00
-474,186.00
-267,892.00
-134,231.00
Normalized Income
-479,437.00
-481,092.00
-460,701.00
-267,892.00
-134,231.00
Interest Income
50,484.00
49,832.00
8,542.00
1,283.00
2,352.00
Net Interest Income
50,484.00
49,832.00
8,542.00
1,283.00
2,352.00
EBIT
-517,336.00
-515,291.00
-458,164.00
-267,850.00
-136,583.00
EBITDA
-507,898.00
-506,315.00
-450,592.00
-260,959.00
-130,272.00
Reconciled Depreciation
9,438.00
8,976.00
7,572.00
6,891.00
6,311.00
Net Income from Continuing Operation Net Minority Interest
-485,502.00
-481,192.00
-474,186.00
-267,892.00
-134,231.00
Total Unusual Items Excluding Goodwill
-6,065.00
-100.00
-13,485.00
--
--
Total Unusual Items
-6,065.00
-100.00
-13,485.00
--
--
Normalized EBITDA
-501,833.00
-506,215.00
-437,107.00
-260,959.00
-130,272.00
12/31/2020 - 5/6/2016
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CRSP CRISPR Therapeutics AG
57.87
-3.49%
CRBU Caribou Biosciences, Inc.
1.9500
-6.70%
BEAM Beam Therapeutics Inc.
23.21
-3.57%
EDIT Editas Medicine, Inc.
5.30
-2.39%
GPCR Structure Therapeutics Inc.
53.07
-4.60%
VKTX Viking Therapeutics, Inc.
55.99
+1.78%
RXRX Recursion Pharmaceuticals, Inc.
8.51
-5.55%
VERV Verve Therapeutics, Inc.
5.21
-1.33%
SMMT Summit Therapeutics Inc.
7.72
-5.04%
DNA Ginkgo Bioworks Holdings, Inc.
0.5141
-6.53%